Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs.
Abenhaim
Lucien
L
D016907:Adverse Drug Reaction Reporting Systems / Q000331:legislation & jurisprudence; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D017277:Drug Approval; D005602:France; D006291:Health Policy; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib